A Phase III Trials Program Exploring the Integration of Bevacizumab, Everolimus (RAD001), and Lapatinib Into Current Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer (GeparQuinto)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2011 by German Breast Group.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
AGO Study Group
Information provided by (Responsible Party):
German Breast Group
ClinicalTrials.gov Identifier:
NCT00567554
First received: December 4, 2007
Last updated: July 11, 2012
Last verified: August 2011
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: December 2015
  Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)
No publications provided by German Breast Group

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):